AllSight
Companies · OLMA · Pharmaceutical Preparations

Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals, Inc. (OLMA) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Olema Pharmaceuticals, Inc. (OLMA) stock — financials & valuation

Key numbers for Olema Pharmaceuticals, Inc. (OLMA): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 36/100 — a percentile rank of Olema Pharmaceuticals, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$723.6M
EV / EBITDA-3.1×
Return on equity-47.5%
ROIC-57.4%
Debt / equity0.0×
Dividend yield0.0%

Is Olema Pharmaceuticals, Inc. overvalued? P/B looks fair vs its 5-year range.

Independent of the events above — derived from Olema Pharmaceuticals, Inc.’s own financial statements and shown as context, never as advice.

Aug 13, 2026CFO appointment
Olema’s CFO search ends just before its biggest clinical and commercial tests
Aug 10, 2026
Enrollment completed, but heavier spending drove an EPS miss
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact